SCHEMBL27008159

SCHEMBL27008159

CC(C)(C)OC(=O)N1CC[C@@H](CCO)[C@H](F)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.46
RECQL P46063 1/20 0.44
NR1H2 P55055 1/20 0.43
MAPT P10636 2/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
KMT2A Q03164 1/20 0.42
EPHX1 P07099 1/20 0.41
DPP4 P27487 1/20 0.40
USP2 O75604 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
GPR119 Q8TDV5 1/20 0.39
JAK2 O60674 1/20 0.38
JAK1 P23458 1/20 0.38
PDE4B Q07343 1/20 0.38
HSD17B10 Q99714 1/20 0.38
KDM4E B2RXH2 1/20 0.38
THRB P10828 1/20 0.38
PTPN2 P17706 1/20 0.38
PTPN1 P18031 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29099052 1.00 HPGD (0.46) HPGDRECQLNR1H2MAPTMEN1
SCHEMBL26978427 1.00 HPGD (0.46) HPGDRECQLNR1H2MAPTMEN1
SCHEMBL26978402 1.00 HPGD (0.46) HPGDRECQLNR1H2MAPTMEN1
SCHEMBL15227941 1.00 HPGD (0.46) HPGDRECQLNR1H2MAPTMEN1
SCHEMBL15227944 1.00 HPGD (0.46) HPGDRECQLNR1H2MAPTMEN1
SCHEMBL27008212 1.00 HPGD (0.46) HPGDRECQLNR1H2MAPTMEN1
SCHEMBL14893333 0.92 HPGD (0.44) HPGDRECQLNR1H2MAPTMEN1
SCHEMBL15227465 0.89 NR1H2 (0.49) HPGDRECQLNR1H2MAPTMEN1
SCHEMBL15716049 0.89 NR1H2 (0.49) HPGDRECQLNR1H2MAPTMEN1
SCHEMBL1991642 0.89 NR1H2 (0.49) HPGDRECQLNR1H2MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4308576-B1 NEW THIAZOLOPYRIMIDINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2025-04-23 EP disclosed
EP-4308576-A1 NEW THIAZOLOPYRIMIDINONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2024-01-24 EP disclosed
US-20240018163-A1 NEW THIAZOLOPYRIMIDINONE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2024-01-18 US disclosed
WO-2022194801-A1 NEW THIAZOLOPYRIMIDINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2022-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018163-A1 NEW THIAZOLOPYRIMIDINONE DERIVATIVES NDUFS3, FOXM1, MT-ND1 HPGD 2371/4885RECQL 671/4885NR1H2 1092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.